MED25 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Norstictic Acid (SCHEMBL13287269)	1.00	1/20
Norstictic Acid (SCHEMBL29369714)	1.00	1/20
Slazinic Acid (SCHEMBL3801772)	0.77	1/20
Stictic Acid (SCHEMBL13495711)	0.77	1/20
SCHEMBL15581642	0.77	1/20
Stictic Acid (SCHEMBL29394416)	0.77	1/20
SCHEMBL17694852	0.76	1/20
SCHEMBL30509240	0.69	1/20
SCHEMBL17049615	0.68	1/20
SCHEMBL15581643	0.66	1/20
SCHEMBL13177747	0.65	1/20
SCHEMBL15125097	0.65	1/20
SCHEMBL15125069	0.64	1/20
SCHEMBL30673387	0.64	1/20
SCHEMBL29362036	0.61	1/20
SCHEMBL2618036	0.58	1/20
SCHEMBL13342686	0.56	1/20
SCHEMBL29670815	0.56	1/20
SCHEMBL17975279	0.56	1/20
SCHEMBL2113613	0.55	1/20

Clinical trials — most relevant to MED25 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword?	PHASE4	UNKNOWN
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Neoadyuvant High-dose of Ifosfamide and Concurrent Radiotherapy in Soft Tissue Sarcoma	PHASE2	COMPLETED
Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema	PHASE2	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Spironolactone and XPB-1 Integrity in the TFIIH Complex	nan	ENROLLING_BY_INVITATION
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults	nan	COMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact	nan	UNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Polycystic Ovary Syndrome in Type 1 Diabetes	nan	NOT_YET_RECRUITING
A Comparison of p53-induced Genes Activation in Patients With and Without Acute Myocardial Infarction	nan	COMPLETED
The Andromeda Study.Predictive Value of Combined Criteria to Tailor Breast Cancer Screening.	nan	COMPLETED
Na+ Channel mRNA Regulation in Heart Failure	nan	COMPLETED
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis	nan	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma	nan	COMPLETED
Family Resilience Initiative Research Program	nan	UNKNOWN
Biocollection in MyeloDysplastic Syndrome (P-MDS)	nan	RECRUITING
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a MED25 binder may also engage these)

Protein	Name	Similarity
Q8VCB2	—	1.000	Q8VCB2 →
A2VE44	—	1.000	A2VE44 →
Q6PEH8	—	0.999	Q6PEH8 →
Q6GP15	—	0.993	Q6GP15 →
A4IHD9	—	0.990	A4IHD9 →
A0A3Q7JC00	—	0.984	A0A3Q7JC00 →
Q5R8Q4	—	0.984	Q5R8Q4 →
Q5ZL54	—	0.980	Q5ZL54 →
Q8R205	—	0.980	Q8R205 →
Q3KR73	—	0.980	Q3KR73 →
B5DF93	—	0.980	B5DF93 →
Q96K80	—	0.979	Q96K80 →
A2RSY1	—	0.978	A2RSY1 →
P78364	—	0.978	P78364 →
Q4VGL6	—	0.978	Q4VGL6 →
Q2NLB0	—	0.978	Q2NLB0 →
Q80TM6	—	0.977	Q80TM6 →
Q96RN5	—	0.977	Q96RN5 →
A1A4Q8	—	0.977	A1A4Q8 →
Q64028	—	0.977	Q64028 →
Q6NZ18	—	0.976	Q6NZ18 →
Q9P2N6	—	0.976	Q9P2N6 →
Q8BMI3	—	0.976	Q8BMI3 →
Q98TW1	—	0.976	Q98TW1 →
A0JM64	—	0.976	A0JM64 →
Q62415	—	0.976	Q62415 →
O88873	—	0.976	O88873 →
Q8C3F2	—	0.975	Q8C3F2 →
Q86TB9	—	0.975	Q86TB9 →
Q9Y2K5	—	0.975	Q9Y2K5 →